Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Patients with acute myeloid leukemia (AML) that relapses after allogeneic hematopoietic cell transplantation (allo-HCT) have dismal outcomes.^1-4 Approximately 30% to 50% of patients with AML who relapse after allo-HCT exhibit major histocompatibility class II (MHC-II) downregulation.^5,6 AML blasts with downregulated MHC-II expression fail to stimulate HLA-mismatched T cells in vitro, suggesting that decreased MHC-II expression may promote immune effector evasion, abrogate the graft-versus-malignancy effect, and promote disease relapse.^5,6 

Interferon gamma (IFN-γ) can restore MHC-II expression.^5,7,8 T-cell immunotherapies targeting AML antigens such as a flotetuzumab (FLZ), a CD123 × CD3 bispecific DART molecule, facilitate T-cell activation and localized IFN-γ release in the presence of AML blasts in addition to MHC-independent killing.^9,10 We hypothesized that AML-directed T-cell immunotherapies upregulate MHC-II on AML blasts by activating T cells to locally release IFN-γ.

FLZ was provided by MacroGenics (Rockville, MD). Human THP-1 cells (American Tissue Culture Collection, Manassas, VA), and primary AML samples with low MHC-II expression at diagnosis and post-HCT relapse were obtained and cultured as previously described.^5,11,12 Human CD3⁺ T lymphocytes were obtained by negative immunomagnetic selection (AutoMACS; Miltenyi Biotec, Auburn, CA).^5,13 CD123-, CD33-, and CD371-directed chimeric antigen receptor (CAR) T cells were generated with a PLVM vector and a third-generation CD28-4-1BB-CD3ζ CAR construct.¹⁴ IFN-γ receptor-1 (IFN-γR1) and β-actin knockout (KO) THP-1 cell lines were generated using CRISPR-Cas9 as previously described.¹⁵ Serial HLA-DR expression patterns, AML blast counts, and IFN-γ serum concentrations from patients treated with FLZ on a phase I to II study (NCT02152956) were obtained as previously described in accordance with the Declaration of Helsinki as per research protocols approved by the institutional review boards of the participating institutions. All participants provided informed consent prior to study enrollment.^16-18 

AML cells were cultured with 10 IU/mL interleukin-2 at the indicated effector-to-target (E:T) ratios, and IFN-γ (PeproTech, Rocky Hill, NJ) was used as a positive control.^9,10 Flow cytometry measuring MHC-II and MHC-I expression was performed using BV421-labeled anti-human HLA-DR, HLA-DP, HLA-DQ (clone Tu39; BD Biosciences) and allophycocyanin-labeled anti-human HLA-A, HLA-B, HLA-C (clone W6/32, BD Biosciences), respectively.^5,19 Flow cytometry was also used to measure live single cell counts using SPHERO AccuCount fluorospheres (Spherotech Inc). Luminex assays (Millipore Sigma, Rockville, MD) measured IFN-γ. Inhibition studies used anti-human IFN-γ (clone B27; BioLegend); anti-human IFN-γR1 (Invitrogen #PA5-47866); companion isotype antibodies (clone MOPC-21, BioLegend and goat immunoglobulin G, Invitrogen); ruxolitinib (Selleck Chemicals, Houston, TX); and baricitinib (ApexBio Technology, Houston, TX). For T-cell activation studies, THP-1 cells were treated with IFN-γ 2 ng/mL (or vehicle) for 24 hours and then washed. THP-1 cells were subsequently replated with HLA-mismatched CD4⁺ T cells, and T-cell proliferation was measured via carboxyfluorescein diacetate succinimidyl ester dilution using flow cytometry.

NOD-scid IL2Rgamma^null mice (Jackson Laboratory, #013062) expressing human interleukin-3, granulocyte-macrophage colony-stimulating factor, and stem cell factor (NSG-S) were irradiated with 250 rads and injected with 10⁶ primary AML cells per mouse. After 5.5 weeks, mice were treated, killed 48 hours later, and analyzed for human AML engraftment and phenotype by flow cytometry. Single-cell RNA sequencing (scRNA-seq) was performed on human cells isolated by immunomagnetic selection.

FASTQs were processed with Cell Ranger v6.0.1 “count” command using default parameters and GRCh38 to 2020-A reference. Data were preprocessed, scaled, normalized, and merged using Seurat v4.1.0.²⁰ Cell types were assigned based on marker expression, including T cells (CD3D, CD3E, CD3G) and AML cells (KIT, CD33, IL3RA). For cell-level and cluster-level differential expression, the “SCT” assay of “FindAllMarkers” was used. To evaluate enriched hallmark gene sets, 38 differentially expressed genes were surveyed using the molecular signatures database hallmark gene sets.

THP-1 express CD123 and intermediate levels of MHC-II at baseline (supplemental Figure 1). The combination of FLZ and human third-party HLA-mismatched CD3⁺ T cells (FLZ + T) upregulated MHC-II surface expression on THP-1 cells by an average of 16-fold (Figure 1A; P < .005) when compared with THP-1 cells cultured with vehicle (phosphate-buffered saline [PBS]), FLZ, or T cells alone. IFN-γ also upregulated MHC-II by an average of sixfold (Figure 1A; P < .0001) when compared with vehicle controls. FLZ + T led to significant killing of THP-1 compared with controls (supplemental Figure 2). Coculture experiments were repeated with 4 CD123-expressing primary human AML samples expressing low MHC-II expression at the time of relapse after allo-HCT (AML-250167, AML-1220117, AML-1592619) or at diagnosis (AML-329614) and again demonstrated that FLZ + T upregulated MHC-II expression (244-fold for AML-250167, P < .00005; 548-fold for AML-329614, P < .005; 34-fold for AML-1220117, P < .001; and 34-fold for AML-1592619, P < .01) compared with T cells alone (Figure 1A). As these primary AML samples contain autologous T cells (E:T ratios ranging from 1:4 to 1:61), addition of FLZ alone also upregulated MHC-II (Figure 1A).

THP-1 and primary AML samples were next cocultured with human CD3⁺ T cells transduced to express a CD123 CART (CART-123). CART-123 cells upregulated MHC-II on THP-1 (16.2-fold, P < .0005), AML-250167 (169-fold, P < .0005), AML-329614 (fourfold, P < .05), AML-1220117 (12-fold, P < .0001), and AML-1592619 (threefold, P < .001) cells when compared with the untransduced (UTD) T-cell controls (Figure 1B). CART-123 led to significant killing of THP-1 compared with controls (supplemental Figure 2). MHC-II upregulation was observed with CAR expressing T cells (CAR-T) cells targeting CD33 (CART-33) or CD371 (CART-371) (supplemental Figure 3).

NSG-S mice were engrafted with AML-250167 cells for 5.5 weeks and divided into 4 treatment groups: (1) vehicle, (2) FLZ, (3) human HLA-mismatched CD3⁺ T cells, and (4) FLZ and T cells. AML-250167 cells engrafted primarily in the bone marrow (supplemental Figure 4). Plasma was collected from blood before euthanasia (48 hours posttreatment). Using scRNA-seq, 34  793 human cells purified from the bone marrow of the mice revealed 6 clusters of human AML cells and 1 human T-cell cluster (Figure 1C). Approximately 80% of AML cells from mice treated with FLZ and T cells were concentrated in cluster 3 (AML_3), and AML cells from the control groups were concentrated in clusters AML_1 and AML_2 (Figure 1C-D). Upregulated genes in AML_3 included (Figure 1E) all MHC-I antigens (HLA-A, HLA-B, HLA-C), nonclassical MHC-I antigens (HLA-E, HLA-F), and MHC-II antigens (HLA-DRA, HLA-DRB, HLA-DPA1, HLA-DPB1). Upregulated gene sets in AML_3 included IFN-γ response genes (Figure 1F). Concordant with scRNA-seq analyses, IFN-γ plasma levels (Figure 1G) and surface expression of MHC-I and MHC-II on the human AML cells were significantly increased in mice treated with T cells and FLZ (Figure 1H-J).

Serial HLA-DR expression patterns of selected refractory AML patients treated with FLZ in a phase I to II study were also evaluated.^16-18 A subset of patients had a transient increase in HLA-DR expression over the course of a 28-day FLZ infusion; a subset had a sustained increase; and a subset had a sustained decrease or variable expression (supplemental Figure 5). Transient and sustained increases in HLA-DR expression appear to correspond with serum IFN-γ concentrations.

FLZ + T or CART-123 treatment significantly increased IFN-γ supernatant levels in vitro (Figure 2A-F). Addition of antibodies neutralizing IFN-γ and IFN-γR1 (CD119) to the THP-1 and AML-250167 in vitro cocultures inhibited MHC-II upregulation (Figure 2G-H). Furthermore, KO of IFN-γR1, but not β-actin, in THP-1 cells inhibited FLZ + T and IFN-γ from upregulating MHC-II (Figure 2I-J). Given that IFN-γ signals through the JAK-STAT pathway, the JAK1/2 inhibitors ruxolitinib and baricitinib were added to the THP-1 and AML-250167 cocultures and also inhibited MHC-II upregulation (Figure 2K-L).²¹ 

We next hypothesized that soluble IFN-γ produced by FLZ-activated T cells would upregulate MHC-II on bystander AML targets not directly contacted by T cells and FLZ. To test this hypothesis, we placed THP-1, FLZ, and T cells (or relevant controls) in the top well of a transwell plate and bystander THP-1 cells in the bottom well. THP-1 cells in both the top and bottom wells demonstrated MHC-II upregulation (Figure 2M). THP-1 cells in the bottom well were then replated, and MHC-II expression was measured serially in the absence of the cytotoxic effects of FLZ and T cells. MHC-II expression peaked at 48 to 72 hours (Figure 2N). Similar results were observed with AML-250167 (Figure 2O-P). Finally, we found that THP-1 cells treated with IFN-γ to induce MHC-II upregulation stimulated HLA-mismatched CD4⁺ T-cell proliferation to a greater degree than THP-1 cells that were not treated with IFN-γ (supplemental Figure 6).

We demonstrated that FLZ and CAR-T cells targeting CD123, CD33, and CD371 upregulate MHC-II expression on AML blasts in vitro and in vivo. We identified IFN-γ as the mediator of this effect, and blockade of IFN-γ through the use of blocking antibodies, KO of IFN-γR1, or inhibition of IFN-γ signaling via blockade of the JAK/STAT pathway prevented FLZ-mediated MHC-II upregulation. Bispecific antibodies represent a promising treatment option for the treatment of relapsed and refractory acute leukemias.^16,22 We provide a novel rationale for the use of IFN-γ, bispecific T-cell engagers, bispecific antibodies, CAR-T, and other T-cell immunotherapies in the posttransplant relapse setting, not only to debulk the malignancy but also to reverse epigenetic MHC-II downregulation on AML blasts and reinvigorate graft-versus-malignancy effect. Encouragingly, we observed significant upregulation of MHC-II on AML blasts in primary human peripheral blood mononuclear cell samples containing very few autologous T cells (E:T ratios as low as 1:61). Clinical trial testing of exogenous IFN-γ (ClinicalTrials.gov ID NCT04628338) or FLZ (ClinicalTrials.gov ID NCT04582864) to treat AML or MDS relapse after allo-HCT are ongoing.

The authors thank the Siteman Flow Cytometry Core for assistance with flow cytometry and the Division of Comparative Medicine at Washington University for their excellent animal care.

This work was supported by grants from the National Institutes of Health, National Cancer Institute (NCI): K08 Program grant (CA222630-01, to M.J.C.), NCI Research Specialist Award (R50 CA211466, to M.P.R.), a Genomics of Acute Myeloid Leukemia Program Project grant (P01 CA101937, to J.F.D.), and an NCI Outstanding Investigator Award (R35 CA197561, to J.F.D.).

Contribution: J.C.R., E.C., and M.P.R. designed and performed experiments, analyzed data, and wrote the manuscript; R.J. analyzed the single cell RNA-seq data and wrote the manuscript; M.J.C., J.K.R., S.C., and M.Y.K. designed and performed experiments; E.B. contributed flotetuzumab; and J.F.D supervised the project, designed the research, and reviewed and edited the manuscript.

Conflict-of-interest disclosure: J.F.D. receives research funding from NeoImmuneTech, MacroGenics, Incyte, Bioline Rx; has equity ownership in Magenta Therapeutics, Wugen; and is a board member for hC Bioscience Inc, RiverVest Venture Partners. E.B. is an employee of MacroGenics, Inc, and receives compensation, stock, and stock options as condition of employment. The remaining authors declare no competing financial interests.

Correspondence: John F. DiPersio, Division of Oncology, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8007, St. Louis, MO 63110; e-mail: [email protected].